Category

India

India: Reliance Industries, Oyo, ITC Ltd, Bharti Airtel, Paradeep Phosphates, Hindustan Unilever, Dr Lal PathLabs Ltd, LIC Housing Finance, RITES Ltd, Lenovo and more

By | Daily Briefs, India

In today’s briefing:

  • NIFTY Indices: Quiddity Primer
  • Oravel Stays (Oyo) Pre-IPO – The Positives – Network Effects Coupled with Industry Tailwinds
  • ITC Ltd (ITC IN) | A Good Place to Hide
  • Bharti Airtel – Tear Sheet – Lucror Analytics
  • Paradeep Phosphates IPO Trading – Tepid Demand and Anchor Quality Isn’t the Greatest
  • Hindustan Unilever (HUVR IN) | The Right Priorities, but Ain’t Enough
  • Dr Lal PathLabs Ltd (DLPL IN): Base Business Recovering; Competition Is the Only Headwind
  • LICHF: Stellar Q4FY22 Results
  • Rites: Robust Order Book & Execution Prowess to Regain Momentum; Retain BUY
  • Morning Views Asia: Adani Ports & Special Economic Zone, Bharti Airtel, Lenovo, Vedanta Resources

NIFTY Indices: Quiddity Primer

By Janaghan Jeyakumar, CFA

  • The NIFTY Index Family has a series of broad equity indices that represents large, mid and small market capitalisation segments of the Indian public equity market.
  • The review of broad market indices will be done on a semi-annual basis and the changes will be implemented at the end of March and September every year.
  • In this insight, we take a look at the selection criteria and the historical price performance of past Rebalance Events.

Oravel Stays (Oyo) Pre-IPO – The Positives – Network Effects Coupled with Industry Tailwinds

By Clarence Chu

  • Oyo (1698548D IN) is looking to raise around US$700m in its upcoming India IPO. The IPO will consist of both a primary and secondary portion.
  • Oyo runs a digital platform that serves as a hotel and home aggregator between patrons, which include owners and lessors, and customers, such as travelers and guests booking for accommodation.
  • As of Mar 2021, Oyo had 157,344 storefronts across more than 35 countries listed on its platform.

ITC Ltd (ITC IN) | A Good Place to Hide

By Pranav Bhavsar

  • ITC Ltd (ITC IN) ‘s core cigarette portfolio is relatively inelastic to the current commodity inflation. With the reopening of offices and social events, volumes are likely to trend higher. 
  • A renewed focus on FMCG is likely to aid volumes for the non-cigarette segment. 
  • Valuations are in favor and we see limited scope for de-rating if not re-rating.

Bharti Airtel – Tear Sheet – Lucror Analytics

By Trung Nguyen

We view Bharti Airtel as “Low Risk” on our LARA scale, mainly driven by its strong market position as the second-largest player in India’s telco industry. It owns robust network infrastructure across India, with a broad customer base. We also like the improving industry outlook with rationalising competition, industry consolidation to Airtel’s advantage, and improving regulatory conditions. Airtel is also committed to prudent balance-sheet management and stable leverage. However, the company will likely face continued significant capex requirements with respect to its 5G rollout, with the associated risks being higher than expected capex.

Our Credit Bias is “Stable”, given Airtel’s robust business risk profile and stable financial metrics.


Paradeep Phosphates IPO Trading – Tepid Demand and Anchor Quality Isn’t the Greatest

By Clarence Chu

  • Paradeep Phosphates raised around US$194m in its India IPO. The IPO consisted of a mix of primary and secondary shares.
  • Subscription for PP’s IPO had been tepid and previous deals with similar subscription rates had produced mixed performances upon debut.
  • Were the firm to trade towards its closer peers’ average, there is a 5% upside potential and -18.6% downside potential on the FY23E and FY24E EV/EBITDA front, respectively. 

Hindustan Unilever (HUVR IN) | The Right Priorities, but Ain’t Enough

By Pranav Bhavsar

  • Hindustan Unilever (HUVR IN) is focusing on protecting its business model and market share, which is the key in such an operating environment. 
  • Presence across multiple price points and playing a targeted game in target geographies will aid in maintaining steady-state growth. 
  • Current valuations, lack of trigger for driving exponential volume growth and expected slowing pace of premiumisation warrant caution. 

Dr Lal PathLabs Ltd (DLPL IN): Base Business Recovering; Competition Is the Only Headwind

By Tina Banerjee

  • Dr Lal PathLabs Ltd (DLPL IN) reported 35% y/y revenue growth in its non-COVID business in FY22. Non-COVID realization per patient is also back to pre-COVID levels.  
  • The company has acquired Suburban Diagnostics last year, which will further widen its geographical footprint, with western region contributing 24% of revenue from 10% earlier.
  • There is a lot of noise regarding competition in the industry. Thus far, DLPL has not seen much pricing pressure and underpenetrated Indian diagnostic segment can accommodate more players.

LICHF: Stellar Q4FY22 Results

By Ankit Agrawal, CFA

  • LIC Housing Finance (LICHF IN) reported stellar results, in line with the expectation from our last note. NIM expanded while provisions declined leading to Q4FY22 PAT of INR 1100cr+.
  • Asset quality improved with Stage 3 assets at 4.64% vs 5.04% QoQ and Stage 2 assets at 3.08% vs 3.75% QoQ. LICHF also recovered 350cr of NPAs during Q4FY22.
  • Adjusted for one-off tax benefits and assuming FY23 NIM at 2.4%, LICHF’s normalized PAT potential is INR 3600cr+ suggesting that LICHF is trading at <6x P/E on FY23E PAT.

Rites: Robust Order Book & Execution Prowess to Regain Momentum; Retain BUY

By Axis Direct

  • RITES Ltd. (RITES) reported a good set of Q4FY22 numbers with revenues of Rs 766 Cr (up 20% YoY), supported by the higher export sales, EBIDTA of Rs 204 Cr (up 10% YoY), and APAT of Rs 141 Cr (down 1% YoY).
  • The company registered EBITDA Margins of 26.7% in Q4FY22 (our estimate: 26.8%) as against 29.2% in Q4FY21
  • We roll over our estimate to FY24 and retain a BUY rating on the stock, valuing the company at 11.5x FY24E EPS to arrive at a target price of Rs 275/share (Rs 305/share earlier), implying an upside of 10% from the CMP.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Morning Views Asia: Adani Ports & Special Economic Zone, Bharti Airtel, Lenovo, Vedanta Resources

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma

India: Britannia Industries, Steel Authority of India, Jyothy Laboratories, Kajaria Ceramics, Kaveri Seed, Mindspace Business Parks REIT, Nuvoco Vistas, Sapphire Foods, Aditya Birla Fashion and Retail Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • Britannia Industries (BRIT IN) | Time for a Good Snack
  • SAIL: Outlook Challenging Despite Robust Performance; Downgrade to HOLD
  • Jyothy Laboratories – Sales in 4QFY22 Were in Line.
  • Kajaria Ceramics – Ramping up of Capacity Shall Support Volume; Operating Margi
  • Kaveri Seeds – Revenue Fell 6% YoY in FY22 Due to Lower Cotton/Maize (Down 24%/16%) Volumes.
  • Mindspace Business Parks REIT – Strong Revival in Physical Occupancy; ROFO Asse
  • Nuvoco Vistas Corporation Ltd – Good Results Amid Challenging Environment
  • Sapphire Foods – Available Always in All Ways
  • Aditya Birla Fashion and Retail – A Strong Recovery in Business, Particularly the Lifestyle
  • Sail – Earnings Beat Driven by Lower RM Costs

Britannia Industries (BRIT IN) | Time for a Good Snack

By Pranav Bhavsar

  • Aggression in adjacencies, market share gains and under indexed rural exposure presents an opportunity. 
  • COGS Inflation, Risk of downgrading in case of a further hike loom and is a potential risk. 
  • YTD Britannia Industries (BRIT IN) is an outperformer and could remain so.

SAIL: Outlook Challenging Despite Robust Performance; Downgrade to HOLD

By Axis Direct

  • SAIL Q4FY22 results were largely in line with our estimates. The company delivered a strong sales volume of 4.706 Million Tonnes (MT), up 8% YoY and 23% QoQ, marginally ahead of our estimate of 4.6 MT.
  • Topline stood at Rs 30,759 Cr, a slight beat vs our estimate of Rs 29,236 Cr and up 32% YoY and 22% QoQ, led by higher steel prices and sales volumes
  • We downgrade the rating on SAIL to HOLD from BUY and value it at 4.0x FY24E EBITDA to arrive at a target price of Rs 75/share (Rs 125/share earlier), against the CMP of Rs74/share.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Jyothy Laboratories – Sales in 4QFY22 Were in Line.

By Motilal Oswal

  • Sales in 4QFY22 were in line. Gross margin was affected due to elevated raw material prices.
  • Revenue growth is key for a company with sales of only ~INR22b. The likelihood of a consistent 15% sales growth (essential for any re-rating) continues to appear difficult, despite JYL’s efforts to ramp up its total and direct reach.
  • With margin likely to remain under pressure over the next few quarters due to high input costs, its earnings growth prospects remain weak.
  •  
  •  

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Kajaria Ceramics – Ramping up of Capacity Shall Support Volume; Operating Margi

By Nirmal Bang

  • Revenue grew by 15.7% YoY and 3.1% QoQ to Rs11,018mn: KCL reported revenue of Rs11,018mn in 4QFY22, up 15.7% YoY and 3.1% QoQ.
  • Revenue from in-house tiles segment grew by 19.1% YoY to Rs5,587mn in 4QFY22 due to growth in blended pricing and volume.
  • The company has taken price hikes at regular intervals, which led to blended realization growth of Rs424/sq mt in 4QFY22 vs Rs417/sq mt in 3QFY22.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Kaveri Seeds – Revenue Fell 6% YoY in FY22 Due to Lower Cotton/Maize (Down 24%/16%) Volumes.

By Motilal Oswal

  • Revenue fell 6% YoY in FY22 due to lower cotton/maize (down 24%/16%) volumes.
  • Cotton seed volumes were impacted by lower cotton acreage and the use of illegal herbicide-tolerant Bt (HTBt) seeds, which impacted sales of branded seeds.
  •  
  • Maize volumes fell due to no sales to the government.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Mindspace Business Parks REIT – Strong Revival in Physical Occupancy; ROFO Asse

By Nirmal Bang

  • Revenue up by 5.9% QoQ and 7.5% YoY in 4QFY22 to Rs4,666mn: Revenue increased by 5.9% QoQ and 7.5% YoY to Rs4,666mn in 4QFY22.
  • EBITDA margin contracts by 190bps QoQ but expands by 690bps YoY in 4QFY22 to 75.1%
  • Adjusted PAT stood at Rs1,262mn in 4QFY22 v/s Rs1,362mn in 3QFY22 and Rs1,143mn in 4QFY21

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Nuvoco Vistas Corporation Ltd – Good Results Amid Challenging Environment

By Nirmal Bang

  • 4QFY22 performance: Nuvoco has reported extremely good set of numbers given the challenging environment with EBITDA of Rs4.25bn against our expectation of Rs3.8bn.
  • Capex update: Nuvoco plans to augment its cement volume by ~2.4mn mt from both north and east regions.
  • Outlook: Given the increased competition in the eastern region post recent capex by various companies, it will be challenging for Nuvoco to sustain this performance.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Sapphire Foods – Available Always in All Ways

By Motilal Oswal

  • The Indian Food Service Industry (FSI) is expected to clock 9% CAGR in the coming years, with QSRs likely to grow faster at 23% CAGR over FY20-25.
  • SAPPHIRE’s new scalable Restaurant economic model is a game-changer. Its omnichannel strategy and reduction in store sizes, along with other elements of the model, have led to a big shift in SAPPHIRE’s unit economics.
  • KFC India’s business is on a strong footing, with a healthy ADS and profitability.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Aditya Birla Fashion and Retail – A Strong Recovery in Business, Particularly the Lifestyle

By Motilal Oswal

  • A strong recovery in business, particularly the Lifestyle segment, saw 59% YoY jump in ABFRL’s 4QFY22 EBITDA backed by 25% YoY revenue growth and 210bp gross margin improvement.
  • Net debt at INR5b too was comfortable even after building inventory for the upcoming season and new stores.
  • With healthy recovery and growth momentum across verticals, we raise our FY23E/24E EBITDA by 7-8%, modeling strong 40% EBITDA CAGR over FY22-24E.
  •  

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Sail – Earnings Beat Driven by Lower RM Costs

By Motilal Oswal

  • SAIL reported an inline revenue at INR308b (up 32 % YoY and 22 % QoQ) in 4QFY22, driven by an improved mix of higher ASP and sales volume.
  • Recently, the government announced various measures to cool down prices (refer Exhibit 1).
  • Coking coal has been hovering above USD 500 for the last four months, The La-Nina phenomenon in Australia is over.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: ITC Ltd, TVS Motor , JSW Steel Ltd, JK Cement Ltd, Advanced Enzyme Technologies, Power Mech Projects Ltd, Ramco Cements, Rossari Biotech, Thermax Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • India Channel Insight #35 | ITC, Britannia, Nestle India, Dabur, Marico
  • TVS Motor (TVSL IN) | Supply Issues & EV Ramp Up the Key
  • Morning Views Asia: Delta Dunia Makmur, Indika Energy, JSW Steel Ltd, Medco Energi, Pakuwon Jati
  • JK Cements: Growth Visibility Intact. Maintain BUY
  • JK Cement Ltd – In-Line Results; New Capex to Drive Volume Growth from FY24
  • Advanced Enzyme Technologies – Near Term Challenges Continue
  • Power Mech Projects – Result Above Expectations; Rs36bn Revenue Guidance Given
  • The Ramco Cement Ltd – Good Sequential Improvement in Profitability
  • Rossari Biotech – Complete Pass-Through Is a Challenge in Formulations Biz
  • Thermax – Weak Profitability Offsets Strong Topline Growth; Strong Order Inflow

India Channel Insight #35 | ITC, Britannia, Nestle India, Dabur, Marico

By Pranav Bhavsar


TVS Motor (TVSL IN) | Supply Issues & EV Ramp Up the Key

By Pranav Bhavsar

  • TVS Motor (TVSL IN)’s market share gains in the premium segment can further accelerate in case of easing supply issues and rural recovery. 
  • While EV may not materially move the volumes in the near term, the ramp-up of the newly launched TVS iQube (EV) will determine the sentiment around the stock. 
  • The sector view is positive, but current valuations are not lucrative enough to ignore capital allocation issues that have been a concern for TVSL. 

Morning Views Asia: Delta Dunia Makmur, Indika Energy, JSW Steel Ltd, Medco Energi, Pakuwon Jati

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


JK Cements: Growth Visibility Intact. Maintain BUY

By Axis Direct

  • JK Cement reported satisfactory volume and revenue growth in Q4FY22, supported by better demand and higher realization in its key markets.
  • The stock is currently trading at 15x/12x FY23E/FY24E EV/EBITDA
  • We value JKCL at 13x FY24E EV/EBITDA to arrive at a TP of Rs 2,800 (Rs 3100 earlier) implying an upside of 15% from the CMP and maintaining our BUY rating on the stock.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


JK Cement Ltd – In-Line Results; New Capex to Drive Volume Growth from FY24

By Nirmal Bang

  • 4QFY22 performance: JKCE reported revenue of Rs22.7bn, up 10.5% YoY, driven by 1% YoY growth in volume and 9.5% YoY growth in realization.
  • Capex plans: Work on the Panna project has started in full swing. Work at both the locations of the integrated plant and grinding units is progressing as per schedule.
  • White cement pricing can increase from hereon: For the past several quarters, white cement realizations have been hovering between Rs11,500/mt and Rs12,000/mt with very limited growth.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Advanced Enzyme Technologies – Near Term Challenges Continue

By Nirmal Bang

  • 4QFY22 earnings performance: ADVENZY’s 4QFY22 revenue declined by ~1% YoY. The Human Nutrition segment, which contributes ~66% to the overall revenue, declined by ~6% YoY whereas the Bio-processing segment declined by ~5% YoY.
  • The Animal Nutrition segment grew by ~15% YoY. Region-wise, overall performance was subdued; however, Europe business was impacted more and declined by 43% YoY.
  • India business, which contributes 45% to the topline, reported ~2% YoY growth. EBITDA declined by ~27% YoY mainly on account of higher other expenses on account of increase in the costs of power & fuel, sales promotion, consulting, freight etc.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Power Mech Projects – Result Above Expectations; Rs36bn Revenue Guidance Given

By Nirmal Bang

  • Strong ordering pipeline, margins to improve going forward: The company has received two orders worth Rs2.97bn in 1QFY23.
  • Working capital position: Working capital days at the end of 4QFY22 saw an improvement to 145 days vs 194 days at the end of 4QFY21 and 180 days at the end of 3QFY22.
  • Outlook: We expect revenue/earnings CAGR of 29.3%/42.4% over FY22-FY24E. Current valuation is inexpensive considering the company’s healthy order book, low D/E and decent RoCE (18% in FY20).

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


The Ramco Cement Ltd – Good Sequential Improvement in Profitability

By Nirmal Bang

  • 4QFY22 performance: TRCL has reported decent set of numbers for 4QFY22, given the cost inflation and pressure on demand & pricing in the market.
  • Capex update: TRCL had earlier commissioned the Jayanthipuram clinker line 3 of the 1.5mn mt clinker unit in June’21 while 9MW WHRS will be commissioned soon.
  • Outlook: Cost environment remains volatile and increased competition has made passing on the increased costs difficult, resulting in relatively lower profitability.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Rossari Biotech – Complete Pass-Through Is a Challenge in Formulations Biz

By Nirmal Bang

  • 4QFY22 earnings performance: ROSSARI’s 4QFY22 consolidated revenue growth of 101% YoY was broadly in line with our estimate.
  • HPPC/TSC/AHN grew by 180%/25%/17% YoY, including acquisitions. Unitop and Tristar revenue came in at Rs1,240mn and Rs495mn, respectively in 4QFY22, with EBITDA margin coming in at ~15% and ~12%, respectively.
  • The share of HPPC revenue increased from 50% in 4QFY21 to 69% in 4QFY22.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Thermax – Weak Profitability Offsets Strong Topline Growth; Strong Order Inflow

By Nirmal Bang

  • Strong order inflow indicates broad-based recovery: Thermax posted consolidated order inflow of Rs33.96bn, up 127% YoY, aided by a broad-based industrial recovery.
  • Other business updates: (1) Chemicals segment margins were affected due to the company’s inability to pass on elevated costs through sufficient price hikes and geopolitical tensions.
  • Outlook and valuation: We expect Thermax to report 34%/46.2% revenue/earnings CAGR over FY22- FY24E. The stock is currently trading at 46.5x FY23E EPS.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: Delhivery, Mindtree Ltd, Jamna Auto Industries, Camlin Fine Sciences, Endurance Technologies Ltd, Krishna Institute of Medical Sciences, Pfizer Limited, Pi Industries, Shree Cement and more

By | Daily Briefs, India

In today’s briefing:

  • Delhivery IPO Trading – Anchor Book Was Good but Overall Demand Was Still Tepid
  • S&P BSE Indices: No Changes for SENSEX; 7 ADDs/DELs for BSE 100 in June 2022
  • Jamna Auto Industries – Ideal Play on CV Upcycle; Resume with Buy
  • Camlin Fine Sciences: RM Pressure Weighs on Performance; Structural Change Underway
  • Result Update – Endurance Tech
  • Endurance Technologies – Multiple Growth Levers to Drive Industry Outperformance
  • Result Update – Krishna Institute of Medical Sciences LTD
  • Pfizer India – Beat on Margins
  • PI Industries: Executional & Operational Improvement. Positive Outlook!
  • Shree Cements Ltd – Lower Pricing Impacts EBITDA; Costs Remain in Control

Delhivery IPO Trading – Anchor Book Was Good but Overall Demand Was Still Tepid

By Sumeet Singh

  • Delhivery raised around US$680m in its India IPO, the company is backed by a host of financial investors, the largest being Softbank.
  • Delhivery is an online logistics service provider which covers express parcel delivery, heavy goods delivery, part truckload (PTL) freight, truckload (TL) freight, supply chain solutions, cross border solutions etc.
  • We have covered various aspects of the deal in our earlier notes. In this note, we talk about the demand and trading dynamics. 

S&P BSE Indices: No Changes for SENSEX; 7 ADDs/DELs for BSE 100 in June 2022

By Janaghan Jeyakumar, CFA

  • After market close on Friday 20th May 2022, the constituency changes for S&P BSE 100, SENSEX 50, and SENSEX Next 50 Indices were announced. 
  • There will be no changes for S&P BSE SENSEX and S&P BSE BANKEX Indices in the June 2022 Rebalance. 
  • These changes will become effective at the open of Monday 20th June 2022. Below is a closer look at each of the names involved in the June 2022 Rebalance.

Jamna Auto Industries – Ideal Play on CV Upcycle; Resume with Buy

By Nirmal Bang

  • Revenue ahead of estimate driven by improving product mix and higher realisation
  • Key beneficiary of a multi-year CV upcycle: We see strong multi-year CV upcycle over the next 2-3 years
  • Rising share of high-margin products & cost-control initiatives to drive margins: Increasing share of more rofitable Parabolic Springs (share of Parabolic Springs has risen to ~37-40% in the last two quarters vs. ~22% FY19) due to vehicle premiumisation should lead to improvement in product mix and profitability.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Camlin Fine Sciences: RM Pressure Weighs on Performance; Structural Change Underway

By Axis Direct

  • Camlin Fine Sciences (CFS) Q4 FY22 performance was lower than our expectations as the company witnessed severe raw material inflation as increased gas prices affected the CFS Euro subsidiary due to the ongoing Russia-Ukraine conflict.
  • Consolidated Revenues stood at Rs 389 Cr, up 19% YoY (our estimate: Rs 377 Cr).
  • With regards to the Lockheed Martin deal, the pilot project with a 1,500-ton capacity has the potential to generate Rs 120-140 Cr revenue with contribution kicking in from FY24 onwards.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Result Update – Endurance Tech

By Axis Direct

  • Domestic business: The standalone revenue declined 3% YoY, impacted by weak 2W industry demand especially in the entry-level segment while production of premium motorcycles was impacted by the shortage of ABS ECUs
  • EU business: Europe’s business reported a strong beat on both topline and margin despite multiple headwinds (weak PV production, RM pressures, and elevated energy costs, among others.).
  • Healthy Order Wins: During FY22, the company won new orders worth Rs 742 Cr from the top domestic OEMs such as HMSI, HMCL, RE, Ather and others (this is excluding order wins from Bajaj Auto) while receiving RFQ of Rs 2,034 Cr. It includes EV orders worth Rs 160 Cr (including Rs 53 Cr for 2W brakes from Ather and Rs 70 Cr for suspension and brakes from Polarity).

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Endurance Technologies – Multiple Growth Levers to Drive Industry Outperformance

By Nirmal Bang

  • Endurance Technologies’ (ENDU) consolidated revenue came in above our estimate by ~15%, mainly on the back of higher realizations following price hikes.
  • Increase in content per vehicle due to premiumisation in the suspension business, new growth opportunities due to import substitution & regulatory tailwinds (alloy wheels and disc brakes), new products like ABS, growing orders in fully machined casting from automotive & non-auto companies and a sharper focus on aftermarket (recently entered tyre distribution business) are the growth levers going forward. ENDU’s wallet share across OEMs has been gradually rising via cross-selling of new products.
  • EV order wins remain key: ENDU is in an advanced stage of discussion with start-ups, in addition to the existing OEMs, to supply them EV products

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Result Update – Krishna Institute of Medical Sciences LTD

By Axis Direct

  • The company’s occupancy rate reduced to 590bps YOY due to COVID 3.0 in Jan’22 but it has since picked up momentum.
  • ARPOB improved to Rs 25,144., led by speciality surgeries into the lungs and heart segment.
  • The business has almost reached the pre-Covid levels with In-Patient (IP) volumes increasing by 25% on a YoY basis.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Pfizer India – Beat on Margins

By Nirmal Bang

  • Resurgence of Covid and potential launch of anti-covid pill Paxlovid in India
  • Potential generic competition in Eliquis in 2HFY23 – we estimate Eliquis sales to be ~Rs1,500mn for Pfizer in India.
  • Impact of Universal Immunization Program on Prevnar sales in Private Markets – Prevnar penetration in the target markets is currently in low single digit and hence we currently are not building in a material decline in the Prevnar opportunity.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


PI Industries: Executional & Operational Improvement. Positive Outlook!

By Axis Direct

  • PI Industries (PIIND) posted a steady quarter in line with our estimates as the company proved its execution & operational capabilities in this volatile environment. The company reported revenue of Rs. 1395 cr higher by 17.7% / 3% YoY/QoQ.
  • EBITDA Margin came in at 22% which was 101 bps higher YoY, led by favourable product mix in export & domestic market and ISAGRO performance, coupled with improved operating leverage
  • The stock currently trades at 47x at FY22 EPS, given strong performance on the export and domestic front we value PIIND at 35x (its FY24E EPS) coming at a Target Price of Rs 3161.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Shree Cements Ltd – Lower Pricing Impacts EBITDA; Costs Remain in Control

By Nirmal Bang

  • 4QFY22 performance: SRCM reported revenue of Rs41bn, up 3.6% YoY and 7% below our estimate.
  • Capex plans: The company has commissioned 3rd clinker line at Chhattisgarh recently, which has total capacity of 4mn mt.
  • This plant will supply clinker for the recently commissioned grinding units in East. SRCM had earlier announced a capex plan, which includes: (1) Setting up of an integrated cement plant in Nawalgarh tehsil of Rajasthan with clinker capacity of 3.8mn mt and cement grinding capacity of 3.5mn mt (2) Setting up of grinding unit in the Purulia district in West Bengal with 3mn mt capacity and (3) Setting up of 106MW solar power plant at various locations. 

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: Dr. Reddy’s Laboratories, Bharti Airtel, Dlf Ltd, Equitas Small Finance Bank , Galaxy Surfactants Ltd, Gland Pharma Ltd, Indraprastha Gas, ITC Ltd, Jk Lakshmi Cement and more

By | Daily Briefs, India

In today’s briefing:

  • Dr. Reddy’s Laboratories (DRRD IN) 4QFY22: Double-Digit Sales Growth; One-Off Charge Impacted Profit
  • 4QFY22 Results Update – Bharti Airtel
  • DLF – Rising Interest Rate Risk Overshadows Strong Performance
  • Dr. Reddy’s Laboratories – Strong Growth Across Business Segments
  • Equitas Small Finance Bank – MD & CEO Resignation to Be an Overhang near Term
  • 4QFY22 Results Update – Galaxy Surfactants
  • Gland Pharma Ltd. – In-Line with Estimates; Upgrade to Buy on Valuation Comfort
  • 4QFY22 Results Update -Indraprastha Gas
  • 4QFY22 Results Update – ITC
  • JK Lakshmi Cement Ltd.- Exceptional Results; Strong Rerating Candidate

Dr. Reddy’s Laboratories (DRRD IN) 4QFY22: Double-Digit Sales Growth; One-Off Charge Impacted Profit

By Tina Banerjee

  • Dr. Reddy’s Laboratories (DRRD IN) reported 15% y/y growth in revenue in Q4, driven by strong performance across all the markets. Adjusted for one-offs, net profit grew 54% y/y.
  • Despite pricing pressure, the U.S. business should continue its growth momentum with better traction in key products launched in FY22 and upcoming new launches, including generic version of Revlimid.
  • Inflationary pressure (raw material, freight), lower offtake of COVID-related products in India, and currency headwinds in emerging markets are some downside risks for the company.

4QFY22 Results Update – Bharti Airtel

By Motilal Oswal

Continues to deliver strong EBITDA and FCF growth – Bharti Airtel (Airtel) witnessed strong EBITDA growth of 9% QoQ and healthy FCF generation driven by 9% ARPU improvement and healthy incremental margin.

Tariff hikes drive strong India Mobile EBITDA growth of 12% QoQ – Airtel’s consolidated revenue/EBITDA rose 6%/9% QoQ (3% above est.) to INR315b/INR160b, respectively, on strong performances of India Mobile and the Home segment.

Key highlights from the management call – Management expects the next round of hike, which could take place in the current fiscal to help reach INR200 target.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


DLF – Rising Interest Rate Risk Overshadows Strong Performance

By Motilal Oswal

  • Strong launch pipeline will continue to drive its sales performance – Sales bookings grew by 2.6x YoY to INR27b (est. INR24b) in 4QFY22. It ended FY22 on a high, with the best ever pre-sales of INR73b (up 136% YoY).
  • Office portfolio on track to deliver 19% rental CAGR over FY22-24 – Occupancy in DCCDL’s Office portfolio increased by 200bp QoQ to 88%, but sustained at 97% in Retail, resulting in a marginal rise in portfolio occupancy to 89%.
  • Key highlights from the management call – Cash flow: DLF is generating an FCF of INR5-7b per quarter and is confident about maintaining a similar run-rate. 

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Dr. Reddy’s Laboratories – Strong Growth Across Business Segments

By Nirmal Bang

  • Dr. Reddy’s reported revenue at Rs54,368mn, up 15% YoY and 2.2% QoQ. EBITDA stood at Rs12,981mn, up 14.6% YoY and 2.5% QoQ.
  • EBITDA margin stood at 23.9%, down 9bps YoY, but up 8bps QoQ. 
  • Profit After Tax (PAT) stood at Rs875mn, down 84.2% YoY and 87.6% QoQ.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Equitas Small Finance Bank – MD & CEO Resignation to Be an Overhang near Term

By Nirmal Bang

  • Will change in MD & CEO impact reverse merger or application for universal bank license?
  • Strong management team to drive growth and profitability: Mr. Murali Vaidyanathan, Head of Liabilities and Mr Rohit Phadke, Head of Assets have been promoted to Executive Director’s position (subject to RBI and shareholders’ approval).
  • Valuation: We have a BUY rating on Equitas Small Finance Bank with a target price (TP) of Rs84.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Results Update – Galaxy Surfactants

By Motilal Oswal

  • Inventory gain and improvement in product mix aids margin – GALSURF reported a beat on our 4QFY22 estimates, with EBITDA (INR/kg) at INR25.2 (98% higher than our estimate, +35% YoY) on inventory gains, new contract terms, and improvement in the product mix.
  • Margin rebounds sharply; revenue marginally above our estimate – Revenue stood at INR10.5b (up 34% YoY and 13% QoQ).
  • Valuation and view – maintain Buy – In FY22, realization stood at INR157/kg, with gross margin at INR46.8/kg (+10% YoY) and EBITDA/kg at INR17.1 (down 10% from INR19/kg in FY21).

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Gland Pharma Ltd. – In-Line with Estimates; Upgrade to Buy on Valuation Comfort

By Nirmal Bang

  • The company has guided for a capex of Rs3,000mn in FY23, which will be invested in the Pashmelyaram facility, API expansion and expansion of Enoxaparin production capacity.
  • The company expects 9-10% revenue growth from new product launches. New product launches are expected to deliver better margins than the existing portfolio.
  • Gland is looking at acquiring late stage complex injectable assets / fermentation API assets.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Results Update -Indraprastha Gas

By Motilal Oswal

  • Concerns remain despite a decent performance in 4QFY22 – IGL reported a beat on our EBITDA estimate, although volumes were strong YoY.
  • Volumes in line; margin is above our estimate – Total volumes were in line at 7.74mmscmd (up 14% YoY and 1% QoQ).
  • Valuation and view – maintain Neutral – IGL can increase its sales volume from new areas such as Rewari, Karnal, and Muzzafarnagar; Haryana City Gas; and the newly awarded GAs in the 10th round — a) Kaithal (Haryana), (b) Ajmer, Pali, and Rajsamand (Rajasthan), and c) Kanpur, Fatehpur, and Hamirpur (Uttar Pradesh).

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Results Update – ITC

By Motilal Oswal

EBITDA and PAT in line; cigarette volumes resilient – ITC’s 4QFY22 EBITDA and PAT growth came in line with our estimates.

Sales beat led by Agri business and Paperboards – ITC’s revenue grew 16.8% YoY to INR155.3b (est. INR138.4b) in 4QFY22.

Valuation and view – ITC’s re-rating would depend on sustained earnings growth going back to the high-teens levels witnessed in the first half of the last decade (at 18% CAGR) which had slowed down to 6.6% CAGR over the latter half of the decade.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


JK Lakshmi Cement Ltd.- Exceptional Results; Strong Rerating Candidate

By Nirmal Bang

  • 4QFY22 performance: JK Lakshmi reported exceptional numbers, with EBITDA coming in at Rs2.76bn, up 3% YoY and 73% ahead of our estimate.
  • Substantial control in costs: The company has been diligently working on optimizing its cost structure and believes that the same has started bearing fruits.
  • Capex plans: Udaipur Cement Work Ltd.’s (UCWL) expansion plan worth Rs16.5bn to add 2.5mn mt capacity in Rajasthan (Rs7bn in the first year and Rs9.5bn in the second year) is expected to be commissioned by FY24.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: TVS Motor , Hero Motocorp and more

By | Daily Briefs, India

In today’s briefing:

  • TVS Motors- Forensic Analysis
  • Hero Motocorp (HMCL IN) | Structural Problems Persist

TVS Motors- Forensic Analysis

By Nitin Mangal

  • TVS Motor (TVSL IN) primary setback is in the form of poor capital allocation
  • In TVS Motors: Analysis Of Various Investments , we had briefed on the investment policy of the company and how the non-core investments/subsidiaries are dragging the profits.
  • This insight is an extension of the previous one; we update on the various investments the company has undergone and how it impacts the capital allocation.

Hero Motocorp (HMCL IN) | Structural Problems Persist

By Pranav Bhavsar

  • We anticipate the uptick in retail primarily aided by the wedding season to be short-lived for Hero Motocorp (HMCL IN)
  • HMCL has not been able to keep pace with changing consumer preferences, the limited success in premium segment and scooters is likely to remain an overhang even on new launches.  
  • Inventory correction at the dealer’s end could aid wholesales supporting valuations, but the company remains structurally unattractive. 

Before it’s here, it’s on Smartkarma

India: Eicher Motors, Dr. Reddy’s Laboratories, Gland Pharma Ltd, Jk Lakshmi Cement, V.I.P. Industries, Xiaomi Corp and more

By | Daily Briefs, India

In today’s briefing:

  • Eicher Motors (EIM IN) | The “Twins” (New Models & Exports) Are Firing
  • Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY
  • Gland Pharma Ltd: Strong Growth Across Geographies to Drive Profitability
  • JK Lakshmi Cement: Robust Performance in Challenging Time; Maintain Buy
  • VIP Industries.: Returning Normalcy, Rewired Business & Regaining Market Share
  • Weekly Wrap – 20 May 2022

Eicher Motors (EIM IN) | The “Twins” (New Models & Exports) Are Firing

By Pranav Bhavsar

  • Eicher Motors (EIM IN) is well-positioned to offset margin pressures due to its aspirational brand, the success of its new models and exports. 
  • Easing supply issues along with newer export markets provide a compelling runway for revenue growth. 
  • While our estimates are in line with consensus,  we believe the YTD outperformance is likely to continue and any opportunities presented amidst market volatility must be exploited. 

Dr Reddys Labs: Stable Results Despite Industry Headwinds; Maintain BUY

By Axis Direct

  • Dr Reddy Q4FY22 reported revenue growth of 14.8% YoY (vs. our expectations of 8.0% YoY), led by strong performance in geographies such as the US, India, and Emerging Markets. 
  • The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio, vaccines, CDMO, and digital healthcare platforms
  • However, high inflation could decrease margins prompting us to reduce TP to Rs 4,500/share.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Gland Pharma Ltd: Strong Growth Across Geographies to Drive Profitability

By Axis Direct

  • Gland Pharma reported a good set of numbers with revenue for the Q4FY22 growing by 24.3% on a YoY basis. 
  • We believe stock trades at rich valuations of PE of 36.2x and 30.4x for FY23E and FY24E respectively
  • We, therefore, recommend a HOLD rating on the stock with a target price of Rs 3,300/share.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


JK Lakshmi Cement: Robust Performance in Challenging Time; Maintain Buy

By Axis Direct

  • JKLC reported strong Volume/Revenue/EBITDA/APAT growth of 8%/13%/3%/26% YoY and 28%/25%/89%/190% QoQ.
  • The encouraging growth on all fronts was on account of higher volume, superior realization, stringent cost management, and lower tax
  • We retain our BUY rating on the stock and roll over our estimate to FY24 and value the company at 7x of its FY24E EV/EBITDA to arrive at a target price of Rs 620/share, implying an upside of 48% from the CMP.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


VIP Industries.: Returning Normalcy, Rewired Business & Regaining Market Share

By Axis Direct

  • VIP Industries (VIP) Q4 FY22 results reported a weak set of numbers given the seasonally weak quarter.
  • Revenue stood at Rs 356 Cr up 46% YoY on account of the low base & down 13% QoQ due to the 3rd wave of Covid-19 Omnicron variant
  • Revising our FY23/24 estimates adjusting for the new cost environment we revise our recommendation from Buy to HOLD with a revised TP of Rs 596/share (earlier: Rs 600/share) valuing the stock at 47x FY24E EPS.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Weekly Wrap – 20 May 2022

By Charles Macgregor

Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.

In this Insight:

  1. China Jinmao Holdings
  2. Guangzhou R&F Properties
  3. Sunac China Holdings
  4. Greenland Hong Kong Holdings
  5. Evergrande

and more…


Before it’s here, it’s on Smartkarma

India: INR 10Y, Indraprastha Gas, ITC Ltd, Kajaria Ceramics, Manappuram Finance, Multi Commodity Exchange India, Pi Industries, Star Cement Ltd and more

By | Daily Briefs, India

In today’s briefing:

  • Yields in Asia Are Far from the Peak – Part II
  • Indraprastha Gas – PAT Beat of 26.9% on Lower Gas Cost
  • ITC: Healthy OverallPerformance
  • ITC Ltd – Robust Operating Performance- Dividend Yield Improves Further
  • HSIE Results Daily: Kajaria Ceramics
  • Manappuram Finance – Customer Acquisition Weak Amid High Competition, Weak Demand
  • 4QFY22 Results Update – MCX
  • PI Industries – Domestic Revenue Growth Outpaces Exports
  • Star Cement: Encouraging Volume Growth; Better Cost Management
  • Star Cement Ltd – Volume Growth Finally Kicks In, Driving Earnings Beat

Yields in Asia Are Far from the Peak – Part II

By Gautam Jain, PhD, CFA

  • Even as the US 10y yield has come off the peak, rates in emerging markets – including in Asia – have been selling off as they remain under pressure.
  • Rates in Asia are vulnerable as they are expensive vis-à-vis the rest of EM, rising inflation should result in further rate hikes in the region, and debt profiles have deteriorated.
  • I thus expect rates in Asia to underperform and prefer selling bonds in the region paired with long bond positions in countries in other regions.

Indraprastha Gas – PAT Beat of 26.9% on Lower Gas Cost

By Nirmal Bang

  • Revenue grew by 55.2% YoY to Rs24.06bn vs NBIE estimate of Rs24.56bn, a 2.1% miss on our estimate and 0.38% miss vs street estimate.
  • Gross margin came in at 36.9% vs our estimate of 32% as COGS was 9.1% below our estimate while revenue miss was 2.1%.
  • PBT was up 33.2% vs NBIE estimate at Rs4.95bn; Share of JV/Associates was a 11.8% beat at Rs723mn.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


ITC: Healthy OverallPerformance

By Axis Direct

  • ITC reported a healthy set of numbers in Q4FY22with Revenue of Rs 15,331Cr (our estimate – Rs16,205Cr), down 2.2%QoQ but up ~16.5% YoY, led by a strong 8% volume growth in Cigarettes (in line with our estimates).
  • Gross Margins at 52.5% was 132bps lower YoY on account of unprecedented RM inflation
  • Benign taxation, inexpensive valuations (20x FY24E EPS), 5% dividend yield makes us BUYers of the stock. Our TP is revised to Rs 295 (earlier Rs 280).

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


ITC Ltd – Robust Operating Performance- Dividend Yield Improves Further

By Nirmal Bang

  • 4QFY22 headline performance: ITC’s 4QFY22 standalone topline (adjusted for excise duty) was up 16.8% YoY at Rs155bn vs our est. of 21.9% YoY growth to Rs162bn.
  • 4QFY22 segmental performance: Cigarette revenue grew by 10% YoY to Rs64.4bn (vs our est. of Rs65.3bn), up ~12% on a two-year CAGR basis.
  • FY22 performance: Standalone Revenue, EBITDA and APAT grew by 23.9%, 22% and 15.5%, respectively.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


HSIE Results Daily: Kajaria Ceramics

By HDFC Securities

  • Q4FY22 performance: Kajaria posted lower-than-estimated margin (~200bps miss) in Q4FY22, as margin compressed QoQ on rising gas prices (crude linked).
  • Tiles sales volumes/revenue rose 2/16% YoY (2-year CAGR 19/29%). Outsourced volume continues to lead growth (+12% YoY, 2-year CAGR 39%).
  • Outlook: For FY23, KJC targets volume/revenue growth of ~15-20%/20-25%.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Manappuram Finance – Customer Acquisition Weak Amid High Competition, Weak Demand

By Nirmal Bang

  • Yields remain under pressure; likely to recover: Net yield in 4QFY22 declined to 18.8% from 20.3% in 3QFY22 and 25.3% in 2QFY22 amid high competition from other lenders.
  • Gold loan AUM down QoQ; uptick in NPA not worrisome: Total gold loans AUM declined 1.4% QoQ while gold holdings/collateral declined by 2.9% QoQ.
  • MFI growth revive in FY23: In 4QFY22, the company scaled back growth in the MFI business as it prioritized improvement in asset quality and collections.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Results Update – MCX

By Motilal Oswal

  • Strong operational performance, an exceptional item impacts PAT –Overall futures ADT improved by 4% QoQ and options ADT jumped by 70%, which resulted in a 19% rise in revenue ahead of our estimate.
  • Healthy volume growth driven by Crude Oil – Total volumes grew 29% YoY and 21% QoQ to INR26t in 4QFY22.
  • Key takeaways from the management commentary – MCX is awaiting approval from the regulators (Sebi and CERC) to launch Electricity derivatives.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


PI Industries – Domestic Revenue Growth Outpaces Exports

By Nirmal Bang

  • Key positives: (i) PI added 8 new customers in FY22 (ii) New thrust on non-agrochem CSM – 35% of its 36 enquiries (iii) PI’s goal is to develop high-value CSM services in Agrochem/Pharma/Specialty Chemicals, based on cost leadership and sustainable manufacturing through differentiated technology/synthesis.
  • We see a bull case/bear case valuation of Rs3,318/Rs2,943 based on 100%/nil impact of the DCF value of a potential M&A deal for a Pharma asset.
  • 4QFY22 results are lower than our estimates. Revenue at Rs13.95bn was a miss of 1.1% vs NBIE estimate, but a beat of 2% vs street estimate.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Star Cement: Encouraging Volume Growth; Better Cost Management

By Axis Direct

  • Star Cement (SCL) reported robust revenue/volume growth of 27%/24%YoY in Q4FY22, driven by higher demand in its operating region. However, lower realization impacted the company’s margins
  • The stock is currently trading at 8x FY23E and 7x FY24E EV/EBITDA
  • We retain our BUY rating on the stock and value the company at 8x FY24E EV/EBITDA to arrive at a target price of Rs 105/share, implying an upside of 14% from the CMP.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Star Cement Ltd – Volume Growth Finally Kicks In, Driving Earnings Beat

By Nirmal Bang

  • 4QFY22 performance: In 4QFY22, the company reported volume growth of 27% YoY (up by 33% QoQ) at 1.15mn mt, which was 20.1% above our estimate.
  • Higher domestic coal sourcing will keep costs lower for STRCEM: The company has used low-cost coal inventory, which was available from CIL (~200k mt). It has a long-term FSA with CIL for 150k mt of coal on an annual basis at a fixed price, which will mitigate the risk of price hikes in the future.
  • Capex and expansion plan: A 3mn mt clinker unit in Meghalaya and a 2mn mt grinding unit in Guwahati are expected to be commissioned by the end of CY23.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: Paradeep Phosphates, Eicher Motors, Bharat Petroleum Corp, Kajaria Ceramics, Minda Corp Ltd, Bajaj Electricals, Steel Strips Wheels, Indian Oil Corp, Indoco Remedies and more

By | Daily Briefs, India

In today’s briefing:

  • Paradeep Phosphates IPO – Smallest of the Lot and Fairly Valued as Well
  • India Channel Insight #34 | Eicher (Royal Enfield), TVS Motors, Hero MotoCorp
  • Morning Views Asia: Bharat Petroleum Corp
  • Kajaria Ceramics – Soaring Gas Prices Dent Margins
  • Minda Corporation – Sustains Healthy Growth; Maintain Accumulate
  • 4QFY22 Result Update – Bajaj Electricals
  • Steel Strips Wheels: Well-Placed to Capitalize on Auto Revival; Outlook Remains Positive
  • IOC- Refining Gain Offset by Marketing Pain
  • Indoco Remedies – Strong Growth in Regulated Markets

Paradeep Phosphates IPO – Smallest of the Lot and Fairly Valued as Well

By Clarence Chu

  • Paradeep Phosphates (75690Z IN) is looking to raise up to US$194m in its India IPO. The IPO will consist of a mix of primary and secondary shares.
  • Paradeep Phosphates (PP) is a fertilizer manufacturing company based in India. The firm engages in manufacturing, trading, distribution and sales of a variety of complex fertilizers.
  • At listing, while PP would be the smallest peer on the revenue and mcap fronts, it trails our identified peer set on the margin front as well.

India Channel Insight #34 | Eicher (Royal Enfield), TVS Motors, Hero MotoCorp

By Pranav Bhavsar

  • We speak to channels across West, North and South to understand the 2W demand environment 
  • Mid segment is still not seeing recovery, premium and lower end segment is stabilising / doing relatively better. 
  • Restoration of supplies and aggressive marketing strategies can aid volume recovery for TVS Motor (TVSL IN) and Eicher Motors (EIM IN) 

Morning Views Asia: Bharat Petroleum Corp

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Kajaria Ceramics – Soaring Gas Prices Dent Margins

By HDFC Securities

  • Q4FY22 performance: Kajaria posted lower-than-estimated margin (~200bps miss) in Q4FY22, as margin compressed QoQ on rising gas prices (crude linked).
  • Outlook: For FY23, KJC targets volume/revenue growth of ~15-20%/20-25%.
  • It expects India’s tiles export to increase by ~35% YoY, as sharp spikes in gas and electricity prices in European countries have increased Indian tile’s competitiveness.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Minda Corporation – Sustains Healthy Growth; Maintain Accumulate

By Nirmal Bang

  • Revenue ahead of estimate; decent operating margin: Revenue for 4QFY22 stood at Rs9.48bn (our est. Rs7.6bn) and was up by 19.4% YoY and 28.4% QoQ, mainly due to consolidation of MIL figures in this quarter (MIL revenue stood at Rs1.38bn).
  • Revenue share from the 2W segment declined slightly, which was in line with the decline in the 2W industry as a whole.
  • Mechatronics, AM & others revenue grew by 6% YoY with 13.4% margin while margin in the ICS segment came in flattish at 7.4%. EBITDA grew by 36.9% QoQ to Rs1,077mn.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Result Update – Bajaj Electricals

By Nirmal Bang

  • Consumer Product segment update: For 4QFY22, Appliance revenue declined by 5.3% YoY due to a high base.
  • EPC Segment Update: EPC sales grew by 5% YoY, mainly due to calibrated and value-accretive scaling.
  • OCF and debt position: BJE generated positive cash flow from operations (CFO) of Rs2.6bn in FY22, making it 12th consecutive quarter of positive CFO.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Steel Strips Wheels: Well-Placed to Capitalize on Auto Revival; Outlook Remains Positive

By Axis Direct

  • We retain our BUY rating on the stock valuing it at 5.5x FY24E EV/EBIDTA arriving at a target price of Rs 1,000/share, (Rs 1,075/ share earlier) implying an upside of 30% from CMP.
  • Steel Strip Wheels Ltd (SSWL) reported a mixed set of numbers in Q4FY22 supported by the improvement in alloy wheels and the PV segment.
  • Revenue for the quarter improved by 24% QoQ to Rs 1,063 Cr (our estimate – Rs 990 Cr). 

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


IOC- Refining Gain Offset by Marketing Pain

By Nirmal Bang

  • Net revenue came in at Rs1,772.9bn vs NBIE estimate of Rs2,071.6bn and a 9% miss vs street; it was up 43.3% YoY.
  • EBITDA stood at Rs116.3bn vs. NBIE estimate of Rs121.8bn and 2.9% miss vs street; it was down 13.8% YoY.
  • 4QFY22 Petchem segment performance was also under pressure – segment revenue was up from Rs63.82bn in 4QFY21 to Rs80

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Indoco Remedies – Strong Growth in Regulated Markets

By Nirmal Bang

  • The company expects to launch 6-7 ophthalmic products in the US. We expect IRL to be the third generic player to launch gCombigan, which has a market size of ~US$400mn in the US market.
  • IRL has enough API and excipients inventory to last for the next two month.
  • Launched 6 new products in the Indian market in FY22, including Subitral, which was the fastest brand to reach Rs10mn sales within just 40 days of its launch

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma

India: Tata Motors Ltd, Poonawalla Fincorp, Bharat Forge, Eris Lifesciences, Glaxosmithkline Pharmaceuticals, Kalpataru Power Transmission, Triveni Turbine, Affle (India) Limited and more

By | Daily Briefs, India

In today’s briefing:

  • Tata Motors – Earnings Flash – Q4 FY 2021-22 Results – Lucror Analytics
  • Poonawalla Fincorp – Execution & Asset Quality Improve; Upgrade to Buy
  • Bharat Forge – Strong All-Round Performance Drives Beat
  • Bharat Forge (Initiating Coverage): Multiple Growth Drivers in Place. BUY
  • Result Update – Bharat Forge
  • Eris Lifesciences – Niche Launches to Aid Growth over the Medium Term
  • GSK Pharma – Muted 4QFY22; Focus Remains on Key Brands to Revitalize Growth
  • Kalpataru Power – All Eyes on Merger
  • 4QFY22 Result Update – Triveni Turbine
  • Affle India: Seasonally Weak Quarter; Outlook Remains Healthy

Tata Motors – Earnings Flash – Q4 FY 2021-22 Results – Lucror Analytics

By Trung Nguyen

Tata Motors’ Q4 and FY 2021-22 results were better than expected. The company delivered lower than estimated losses and q-o-q improvement in cash flows. That said, the financial risk profile deteriorated significantly due to decreased earnings, albeit partly cushioned by lower debt (driven by cash release from working capital). Liquidity remains sound.

We expect the operating environment to remain difficult in and perhaps even beyond FY 2022-23. We derive comfort from the increasing order book, even though it currently only accounts for c. 50% of full-year deliveries and is hence insufficient for firm revenue visibility. That said, the expanding order book indicates that demand for Jaguar Land Rover exceeds the company’s ability to deliver.


Poonawalla Fincorp – Execution & Asset Quality Improve; Upgrade to Buy

By Nirmal Bang

  • Organic disbursements at Rs22bn and inorganic disbursements stood at Rs11.4bn.
  • March’22 disbursement of pre-owned cars stood at Rs1.65bn (entered leadership position); LTP March’22 disbursements stood at Rs1bn (entered leadership position) and SME LAP March’22 disbursement stood at Rs1bn.
  • Added digital consumption loan product to the retail product portfolio through the partnership mode.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Bharat Forge – Strong All-Round Performance Drives Beat

By Motilal Oswal

  • Core businesses to see sustained recovery in FY23; geographical expansion on the cards
  • Non-auto business grows both in the domestic and export markets
  • Highlights from the management interaction – In FY22, the Indian operations have received new orders of ~INR10b p.a. and the US operations have won new orders worth USD150m p.a.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Bharat Forge (Initiating Coverage): Multiple Growth Drivers in Place. BUY

By HDFC Securities

  • Domestic business sees strong growth momentum in key segments
  • New order wins to drive strong export growth – BHFC’s strong export momentum is likely to continue over FY22-24E, (1) strong demand in CV segment, both in the US and Europe, which would be visible in BHFC numbers as the chip shortage impact gradually wanes away in the coming quarters; (2) new order wins in PVs (management has guided for 30% growth in FY23E); (3) huge opportunities in renewable business globally in multiple sectors and stable demand from oil and gas segment.
  • Subsidiary business performance likely to improve further – Post the restructuring of overseas subsidiaries, its margin has improved to 10% in FY22, from 5% in FY21.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Result Update – Bharat Forge

By Emkay

  • What we like? 1) In FY22, the Indian operations secured new orders worth ~Rs10bn across automotive and industrial applications.
  • EBITDA above estimates: Revenue grew by 28% yoy to Rs16.7bn (est.: Rs15bn), above estimates due to higher sales in the domestic industrials and overseas auto segments.
  • Maintain Buy with a TP of Rs810, based on 24x P/E for the standalone business on Jun’24E EPS.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Eris Lifesciences – Niche Launches to Aid Growth over the Medium Term

By Motilal Oswal

  • Promising start for Drolute and Xsulin – The Dydrogesterone market is at an interesting phase, with an improvement in demand due to better access, affordability, and technical superiority over Progesterone.
  • Favorable demand-supply and marketing efforts to drive ‘Drolute’ sales for ERIS
  • Well-positioned to gain market share in the Insulin market – ERIS has expanded its Anti-Diabetic offering, with the recent launch of human/premix Insulin

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


GSK Pharma – Muted 4QFY22; Focus Remains on Key Brands to Revitalize Growth

By Motilal Oswal

  • Slower offtake witnessed in the Vaccine segment – GLXO delivered a lower-than-expected performance in 4QFY22. Subdued YoY growth in sales and higher raw material cost affected profitability.
  • One-off tax provision leads to a quarterly loss – Revenue was up 9% YoY to INR8.1b (est. of INR9.2b).
  • Key takeaways – Secondary sales data from AIOCD indicates that Pain therapy/Anti-Infective/ Dermatology (~12%/~25%/~28% of overall sales) saw a growth of ~39%/ 21%/5% YoY in 4QFY22, driving the outperformance against IPM.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Kalpataru Power – All Eyes on Merger

By Emkay

  • KPTL results highlights: A lower order book and delays in dispatch led to an 8% revenue decline in FY22, with a margin decline of ~130bps.
  • JMC Projects results highlights: JMC Projects delivered 45% revenue growth on the back of a very strong order book (Book-to-bill of ~4x), better than management’s guidance of 20% growth.
  • Large projects: KPTL has been bidding for large projects in the recent past and recently bagged a large HVDC order worth Rs32bn.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


4QFY22 Result Update – Triveni Turbine

By Nirmal Bang

  • Domestic market update: In FY22, the domestic market under 30MW is estimated to have grown by 71% YoY in MW terms.
  • Exports update: The international market under 30MW is estimated to have declined by 24% YoY in FY22 in MW terms.
  • mpact of Russia-Ukraine conflict: TTL has reduced orderbook by Rs400mn due to the Russia-Ukraine conflict as it took out certain orders from steel mills in Ukraine due to lack of visibility.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Affle India: Seasonally Weak Quarter; Outlook Remains Healthy

By Axis Direct

  • Affle Ltd. (Affle) reported a strong growth backed by robust device addition. The company’s Q4FY21 revenue stood at Rs 315 Cr, decline 7.2% QoQ and grew 123% YoY due to seasonally weak demand during the quarter.
  • Its Operating Margins decline by 130bps QoQ to 18.6% (in line with the management expectations) due higher inventory and data cost
  • We recommend a BUY on the stock and assign a 32x P/E multiple to its FY24E earnings of Rs 35.94/share which gives a TP of Rs 1,140/share, implying an upside potential of 18% from CMP.

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.


Before it’s here, it’s on Smartkarma